AbbVie (ABBV) News Today

AbbVie Inc. (NYSE: ABBV) remains near its all-time high as investors favor defensive healthcare stocks and respond to supportive pipeline news. Recent trading has been influenced by bullish options activity, favorable analyst commentary and encouraging clinical data, although valuation and mixed reactions to new Skyrizi data remain risks ahead of the company’s October 30 earnings report.

• Positive Sentiment: Investors purchased approximately 86,296 ABBV call options, roughly 445% above typical daily call volume, signaling increased bullish interest in AbbVie’s shares. Stock Traders Purchase High Volume of Call Options on AbbVie
• Positive Sentiment: Erste Group Bank issued a positive outlook for AbbVie’s earnings, adding to a series of constructive analyst views. RBC has also reaffirmed its Outperform rating. Erste Group Bank Issues Positive Outlook for AbbVie Earnings Royal Bank of Canada Reaffirms Outperform Rating for AbbVie
• Positive Sentiment: AbbVie and Genmab reported Phase 3 results showing epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed high-risk diffuse large B-cell lymphoma. The result strengthens AbbVie’s oncology growth opportunity. What Does AbbVie 51% DLBCL Risk Reduction Mean For Its Oncology Push?
• Positive Sentiment: Healthcare shares have benefited from a rotation away from technology stocks toward defensive, large-cap companies. AbbVie closed near a record high alongside gains across the pharmaceutical sector. Big Pharma Stocks Close Near All-Time Highs
• Neutral Sentiment: AbbVie is scheduled to report third-quarter 2026 results on October 30. Investors will focus on Skyrizi and Rinvoq growth, post-Humira replacement trends and updated guidance. AbbVie’s Q3 2026 Earnings: What to Expect
• Negative Sentiment: Despite encouraging subcutaneous Skyrizi Crohn’s disease data, one report characterized the market reaction as a 3.1% decline, highlighting that investors may already have high expectations for the immunology franchise. AbbVie’s elevated valuation and some analyst targets below its recent trading level could also limit further upside. AbbVie Drops 3.1% as New Skyrizi Phase 3 Data Hits the Wire